Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4

Abstract

The present invention is directed to a monoclonal antibody that recognizes human FGFR4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody and methods of use thereof.

What is claimed is: 
     
       1. An isolated monoclonal antibody produced by hybridoma cell line BT53, ATCC accession number PTA-121019. 
     
     
       2. The monoclonal antibody of  claim 1 , wherein the antibody is labeled. 
     
     
       3. The monoclonal antibody of  claim 2 , wherein the antibody is labeled with one or more labels selected from the group consisting of a biotin label, a fluorescent label, an enzyme label, a coenzyme label, a chemiluminescent label, and a radioactive isotope label. 
     
     
       4. A method of making a monoclonal antibody, the method comprising providing hybridoma cell line BT53, ATCC accession number PTA-121019, which produces a monoclonal antibody specific for human native fibroblast growth factor receptor 4, and culturing the hybridoma cell line BT53 under conditions that permit the production of the monoclonal antibody. 
     
     
       5. The method of  claim 4  and further comprising coupling a label to the monoclonal antibody. 
     
     
       6. The method of  claim 5 , wherein the label is selected from the group consisting of a biotin label, a fluorescent label, an enzyme label, a coenzyme label, a chemiluminescent label, and a radioactive isotope label. 
     
     
       7. The method of  claim 4 , wherein the monoclonal antibody specifically binds to the amino acid sequence of SEQ ID NO:2 and further comprising coupling a label to the monoclonal antibody with a fluorescent label, a chemiluminescent label, a biotin label, or a radioactive isotope label.